Open access peer-reviewed chapter

The Causative Agent of FMD Disease

Written By

Yaxin Wang and Meijun Liu

Submitted: 05 April 2020 Reviewed: 09 July 2020 Published: 05 November 2020

DOI: 10.5772/intechopen.93349

From the Edited Volume

Some RNA Viruses

Edited by Yogendra Shah and Eltayb Abuelzein

Chapter metrics overview

957 Chapter Downloads

View Full Metrics

Abstract

Foot-and-mouth disease (FMD) is an acute infection of cloven-hoofed animals caused by foot-and-mouth disease virus (FMDV). It is one of the most serious infectious diseases affecting animal husbandry and a major impediment to international trade in livestock and their products. Foot-and-mouth disease virus (FMDV), a member of the Picornaviridae family of Aphthovirus, is an icosahedral virus without envelope, 25–30 nm in diameter, containing about 8.4 kb of positive-sense single-stranded RNA. The virus exists in seven different serotypes: A, O, C, Asia1, SAT1, SAT2, and SAT3, but a large number of subtypes have evolved in each serotype. This chapter reviews the genome, structure, serotype, and epidemiology of FMDV, which will help people to further explore the mechanism of the interaction between foot-and-mouth disease virus and host and provide reference for scientific prevention and control of FMDV.

Keywords

  • FMDV
  • structure
  • serotypes
  • epidemiology

1. Introduction

Foot-and-mouth disease (FMD) is an acute and highly contagious disease of cloven-hoofed animals, such as pigs, cattle, sheep, and many wild animals. Disease animals are much show fever, the place such as snout, feet, and breast forms blister and canker. The disease can spread rapidly in many ways. It has broken out many times in the world, causing huge political and economic losses to human beings. The disease was first discovered in 1514 by the Italian monk H. Fracastorius in cattle. In 1897, Loeffler and Frosch demonstrated that a filterable agent caused FMD is the foot-and-mouth disease virus (FMDV) [1]. The causative agent of FMD disease belongs to the family Picornaviridae, genus Aphthovirus. This chapter describes the status of the genome, structure, serotype, and epidemiology of the virus.

Advertisement

2. The genome of FMDV

The FMDV genome is a positive-sense single-stranded RNA virus with a size of about 8.5 kb [2]. FMDV RNA has a 5′ non-coding region on the left, an open reading frame (ORF) in the middle, and a 3′ non-coding region on the right. At the end of the 5′ non-coding region is a viral coding peptide VPg (or 3B), which is covalently bound to the genome. For FMDV, this 5′ untranslated region (UTR) contains S-fragment (short fragment of the genome), poly(C), pseudoknot, cre structures, and internal ribosome entry site (IRES) [3].

The S fragment can form an over 350 bases stem-ring structure, which is isolated from the genome by a variable length homopolymeric cytidylic acid tract (poly(C)), and there are some differences between the S fragments of different serotypes [4]. Carrillo et al. isolated S fragments with a sequence similarity of 80%, indicating that S fragments are highly conservative [5]. The S fragment can protect the successful replication of daughter RNA and will not be degraded by nucleic acid exonuclease, which greatly ensures the replication process of viral RNA. S fragment was involved in mediating the innate immune system. Kloc et al. found that viral RNA could not survive after deletion of more than 163 nt on stem ring of S fragment [6]. In addition, a short fragment of the G320T mutation prevented rescue of viable virus [7].

Different isolates of FMDV have different lengths of poly(C) tract; Harris and Brown found that the length of poly(C) tract may be related to the virulence of FMDV by comparing a virulent and an avirulent strain of foot-and-mouth disease virus [8]. However, other researchers suggest that the differences in virulence may be due to changes elsewhere in the genome of these strains [3].

The poly (C) tract is followed by three to four tandemly repeated pseudoknots (PKs) [9]. In a recent study, researchers compared the virulence and pathogenic mechanism of different FMDV strains in pigs and cattle by constructing PK recombinant FMDV strains and found that the absence of different sizes of PKs resulted in different pathogeny to the host, indicating that the pseudoknot region was the key to determine the viral tropism and virulence of foot-and-mouth disease virus [10].

In some picornavirus genome coding region, there is a known as cis-acting replicative element (cre) of the basic structure of RNA, cre is a conservative AAACA motif of stem loop structure, its function is to add U residues to the protein primer 3B [11]. Furthermore, Mason et al. found that cre plays an important role in genome replication and that this function is independent of its position at the 5′ end of the genome [12].

Eukaryotes generally begin translation by identifying cap structures at the 5′ end of mRNA; however, the initiation of translation can also occur internally, as has been found in picornavirus RNAs, where a functional element called the internal ribosomal entry site (IRES) at the 5′ end of mRNA also performs this function [13]. The FMDV IRES consists of 462 nucleotides with 5 domains [14]. Earlier studies have found that the interaction between IRES and the translation initiation factor eIF4G, which acts as a linker during translation initiation, is the key to in vivo translation [15]. Later, the researchers found an interaction between the IRES of FMD virus and three other translation initiation factors eIF3, eIF4B, and eIF4GII during translation initiation [16]. Furthermore, IRES trans-acting factor (ITAF) (45) promoted IRES-mediated translation in all cells; however, IRES-mediated translation activity was independent of the host range of FMDV, and only the effects of poly-pyrimidine tract binding protein (PTB) and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) were observed in FMDV-sensitive cells [17]. In addition, Ras GTPase SH3 domain binding protein 1 (G3BP1) interacts directly with FMDV IRES to negatively regulate translation [18].

The genome of FMDV contains an open reading frame, and ORF encodes four structural proteins (VP1, VP2, VP3, and VP4) and 10 non-structural proteins (L, 2A, 2B, 2C, 3A, 3B1, 3B2, 3B3, 3C, and 3D), whose functions will be detailed in the following sections [19, 20].

The 3′ -terminal region of FMDV consists of two distinct elements, a 90 nt untranslated region (3′-NCR) and a poly(A) tract, which have been found to stimulate IRES-driven translation [21]. Since the IRES are located at the 5′ UTR, it was assumed that there was a connection between the 3′ and 5′ ends of FMDV, and Serrano et al. subsequently demonstrated that different 3′ UTR elements are involved in the interaction between the IRES and the S region, suggesting that the 5′-3′ end of the bridge is in direct RNA-RNA contact and plays a role in RNA replication [22]. The absence of SL1 and SL2, two stem-ring structures in the 3′ non-coding region, affects viral infectivity, and the ΔSL1 mutation has been shown in pigs to be harmless to pigs, but to induce an immune response, which is important for the development of FMDV vaccines [23]. In addition, SL2 is an essential component of virus replication [23, 24].

Advertisement

3. Structure of the FMDV

3.1 Structural proteins

FMDV is an icosahedral symmetry non-enveloped virus. It consists of four capsid proteins VP1, VP2, VP3, and VP4, among which VP1, VP2, and VP3 are in the outermost layer of the virus, and VP4 is located in the interior of the virus and contacts with RNA [25]. Malik et al. obtained a high-resolution structure (5.2 Å) of the icosahedron of FMDV using cryo-electron microscopy (cryo-EM), notably, the obtained structure did not contain VP4 [26]. FMDV capsids are susceptible to low pH and high temperature and dissociate into pentamers under acidic conditions and release RNA [27].

In 1982, Barteling et al. proposed that FMDV structural protein (VP1) might be involved in early virus-cell interactions [28]. In the second year, Dawe and King found that the early and late viral virulence obtained by infecting BHK21 cells was different, and the researchers found that the point mutations of the VP1 were the cause of mouse virulence and BHK21 cell pathogenicity [29]. Since most of the VP1 protein is exposed on the surface of the virus, which determines the antigenicity of the virus to a large extent, VP1 protein can induce the body to produce specific neutralizing antibodies and induce anti-infection immunity [30, 31, 32, 33, 34]. On the VP1 of FMDV, there is a well-known G-H loop containing a highly conserved Arg-Gly-Asp (RGD) sequence, which is necessary for the virus to adhere to the cell [35, 36]. The researchers used this property of VP1 to make many explorations in the development of a vaccine against FMDV [33, 37, 38, 39, 40, 41, 42]. In addition, studies have shown that VP1 N terminal is related to pH stability of FMD virus particles [43]. A recent study showed that VP1 inhibits the beta interferon signaling pathways by inhibiting IRF3 phosphorylation, dimerization, and nuclear translocation. However, the DnaJ heat shock protein family (Hsp40) member A3 (DNAJA3) can attenuate this effect [44].

For the structural protein VP2, the researchers believe that VP2 is associated with the persistence of FMDV [45]. Amino acid substitutions in the B-C loop of VP2 protein lead to antigenic differences in different types of FMDV, which indicates that VP2 is related to the antigenic diversity of FMDV [46]. In addition, amino acid substitutions in VP2 also affect the replication ability and virulence of the virus [46]. Interestingly, Vazquez-Calvo et al. found that tyrosine replacement of VP2 histidine enhanced the acid resistance of the FMDV capsid [47]. Further studies have shown that VP2 activates the EIF2S1-ATF4 pathway in cells and induces autophagy via the heat shock protein family B [small] member 1 (HSPB1) [48]. In addition, the researchers found applications for VP2 in vaccine development [49, 50] and detection of viral serotypes [51, 52, 53].

VP3 protein is the structural protein of FMDV. An amino acid deficiency of VP3 protein at position 59 of a foot-and-mouth disease virus was found in India, and the presence of this mutant increased the incidence of the epidemic [54, 55, 56]. In addition, the substitution of VP3 H142D for FMD virus can enhance the acid resistance of serotype A [57]. Furthermore, the researchers found that FMDV VP3 inhibited the IFN-beta signaling pathways [58] and the IFN-gamma signal transduction pathways [59]. Interestingly, Qi et al. found that host microRNA miR-1307 promotes the degradation of the viral structural protein VP3 through the proteasome pathway, suggesting that it may be developed for the treatment of foot-and-mouth disease [60].

Regions 20 to 35 of FMDV VP4 may be involved in inducing an immune response in T cells to recognize the T cell epitopes of MHC, a property that could be used to develop peptide vaccines [61, 62].

3.2 Nonstructural proteins of the FMDV

There are two initiation codes AUG in the ORF of FMDV, which can produce two forms of lead proteases, Lab (synthesized by the first AUG) and Lb (synthesized by the second AUG) [63]. Further studies found that the virus could still be produced in transfected cells when the first AUG was deleted, but not when the second AUG was deleted [64]. FMDV inhibits protein synthesis in host cells after infecting the host, which may be related to the cleavage of eukaryotic translation initiation factor 4GII (eIF4GII) induced by leader protease (L-pro) [65]. Further studies by Moral-Lopez et al. found that L-pro can increase the translation driven by IRES [66]. In addition, phylogenetic analysis of nucleotide sequence in L-pro region of FMD type O serum isolates from India revealed that all amino acid residues at the active cleavage site of L-pro sequence were conserved [67].

The P2 portion of FMDV is eventually processed into three mature peptides, 2A, 2B, and 2C [68]. FMDV 2A protein can cleave the site of 2A/2B, and the researchers applied this property to the field of biotechnology and successfully obtained bioactive proteins by expressing multiple proteins in cells [69, 70, 71, 72, 73, 74, 75, 76]. It has been shown that the 2A polypeptide can cleaving the 2A/2B junction because it has a conserved c-terminal motif [D(V/I)E(S/T)NPGP], where the last P is the first residue of 2B, which is important for protein processing and virus replication [77, 78]. The researchers produced recombinant antigen of FMDV P1-2A3C in plant species, which can induce humoral immunity in guinea pigs [79]. In addition, the development of a genetically engineered vaccine against FMDV 2A may be an effective means of controlling foot-and-mouth disease [80, 81]. The study of 2B by Zhu et al. showed that, in the study of FMDV, 2B expression reduced the expression of retinoic acid-inducible gene I (RIG-I) through the interaction of residues of 2B carboxyl terminal amino acids 105–114 [82]. Further studies have shown that 2B also interacts with MDA5 and negatively regulates RLR-mediated IFN-beta induction [83]. In addition, Zhi et al. demonstrated that 2B activates NLRP3 inflammasome [84]. Further studies revealed that the non-structural protein 2B of FMDV interacts with eEF1G [85] and CypA [86] and plays a role in the process of virus infection and replication. For 2C, it was used to distinguish between infected and vaccinated animals [87, 88, 89, 90]. The researchers identified 2C interacting proteins, including autophagy regulators Beclin1 [91], N-myc, and STAT interactor (Nmi) [92, 93], by yeast two-hybrid system and immunoprecipitation, which are helpful in understanding the mechanism of FMDV.

Similarly, the researchers were able to identify infected and vaccinated animals using non-structural protein 3A [94], which was more specific and sensitive than other non-structural proteins 3B and 3AB [95]. By means of yeast double hybridization, Gladue et al. identified that the interaction between 3A and host protein DCTN3 affected viral virulence [96]. In 2013, a study found that a partial deletion of 3A attenuated the foot-and-mouth disease virus in cattle [97], after 5 years, further research found that the deletion did not prevent subclinical infection [98]. The genome of FMDV contains three copies of the 3B protein (or VPg). In addition, 3A was found to inhibit interferon-beta signaling to evade the host immune system [99]. The study indicates that the 3B copy number is closely related to the virulence of the virus, and the virus containing a single 3B is less virulent, producing only mild disease [100]. By acting on the FMDV capsid precursor, P2-2A, 3C protease cleaved it into VPO, VP3, VP1, and 2A, and these three cleaved independently of each other [101]. Birtley et al. obtained a crystal structure with a resolution of 1.9 Å of 3C protease, which was folded like chymotrypsin and had a cys-his-asp catalytic triad [102]. It has been shown that 3C also attacks the host cytoskeleton during FMDV attack on the host [103]. Further studies showed that 3C protease could inhibit autophagy by degrading the autophagy-related protein ATG5-ATG12 [104]. The last non-structural protein is RNA-dependent RNA polymerase, 3D polymerase. Studies have shown that the synthesis of microRNA targeting 3D polymerase can effectively inhibit the replication of FMD virus in vitro [105, 106]. Therefore, 3D polymerase is one of the effective targets for the development of antiviral drugs targeting FMDV. 5D9, a 3D polymerase inhibitor, can effectively inhibit the replication of FMDV in host cells [107]. There are still many problems to be solved, and the specific function and mechanism of FMD virus non-structural proteins need to be further explored by researchers.

Advertisement

4. Serotypes of the FMDV

There are seven serotypes of foot-and-mouth disease virus divided into A, O, C, Asia-1, SAT 1, SAT 2, and SAT 3, and there are many subtypes of each serotype. Most of the world has had outbreaks of foot-and-mouth disease, the most common of which is serotype O. Six of the seven serotypes (A, O, C, SAT1, SAT2, and SAT3) have occurred in Africa, while four serotypes (O, A, C, Asia1) in Asia and only three serotypes (O, A, C) in South America [108]. However, there are also SAT 1 and SAT 2 viruses from as well as from Africa entering the Middle East [108]. In addition, the most recent outbreak of foot-and-mouth disease caused by serotype C virus occurred in 2004 and is now probably extinct [109].

Advertisement

5. Epidemiology of the FMDV

The epidemiology of FMDV includes the source of infection and the route of transmission. Foot-and-mouth disease (FMD) has the epidemiological characteristics of rapid epidemic, wide spread, and acute onset. The main source of infection is sick animals and the incubation period of animals, the incubation period 1–7 days, the average 2-4 days. Foot-and-mouth disease mainly affects artiodactyls, mainly cattle, especially calves, followed by pigs, camels, sheep, goats, and wild animals. In addition, the virus was found in blisters, milk, urine, saliva, tears, and feces of sick animals. The transmission route is extensive, which can be transmitted to susceptible animals either by direct contact or by indirect contact (e.g., secretions, feces, animal products, contaminated air, feed, etc.). Foot-and-mouth disease occurs frequently in the spring and fall. Clinical features are blister rash in the oral mucosa, hoof, and breast skin. This disease has broken out in the world several times, causing huge political and economic losses.

Advertisement

6. Conclusions

Foot-and-mouth disease will reduce the milk production of sick animals; severe cases will cause acute death; animal husbandry production caused a great loss, so many countries in the world to foot-and-mouth disease as the most important animal quarantine object. In the world, the United States and other developed countries have completely eliminated foot-and-mouth disease; however, in the developing countries, foot-and-mouth disease still exists. There are seven serotypes of FMD virus, which cannot be immune to each other due to their different antigens. Vaccination is a reliable and effective method for specific prevention of FMD, and a safe and effective vaccine is a prerequisite for the successful prevention, control, and eventual elimination of FMD. Therefore, in order to effectively prevent and control foot-and-mouth disease, it is necessary to thoroughly study the mechanism of action of the virus and develop more effective prevention and control methods to ensure the healthy development of animal husbandry.

References

  1. 1. Brown F. The history of research in foot-and-mouth disease. Virus Research. 2003;91(1):3-7. DOI: 10.1016/s0168-1702(02)00268-x
  2. 2. Domingo E, Baranowski E, Escarmis C, Sobrino F. Foot-and-mouth disease virus. Comparative Immunology, Microbiology and Infectious Diseases. 2002;25(5-6):297-308. DOI: 10.1016/S0147-9571(02)00027-9
  3. 3. Mason PW, Grubman MJ, Baxt B. Molecular basis of pathogenesis of FMDV. Virus Research. 2003;91(1):9-32. DOI: 10.1016/s0168-1702(02)00257-5
  4. 4. Bunch T, Rieder E, Mason P. Sequence of the S fragment of foot-and-mouth disease virus type A12. Virus Genes. 1994;8(2):173-175. DOI: 10.1007/bf01703076
  5. 5. Carrillo C, Tulman ER, Delhon G, Lu Z, Carreno A, Vagnozzi A, et al. Comparative genomics of foot-and-mouth disease virus. Journal of Virology. 2005;79(10):6487-6504. DOI: 10.1128/JVI.79.10.6487-6504.2005
  6. 6. Kloc A, Segundo FDS, Schafer EA, Rai DK, Kenney M, Santos TDL, et al. Foot-and-mouth disease virus 5′-terminal S fragment is required for replication and modulation of the innate immune response in host cells. Virology. 2017;512:132-143. DOI: 10.1016/j.virol.2017.08.036
  7. 7. Mohapatra JK, Pandey LK, Pattnaik B. RNA structure disrupting G320-T transversion within the short fragment of the 5′ untranslated region prevents rescue of infectious foot-and-mouth disease virus. Journal of Virological Methods. 2014;196:100-103. DOI: 10.1016/j.jviromet.2013.11.007
  8. 8. Harris TJ, Brown F. Biochemical analysis of a virulent and an avirulent strain of foot-and-mouth disease virus. The Journal of General Virology. 1977;34(1):87-105. DOI: 10.1099/0022-1317-34-1-87
  9. 9. Clarke BE, Brown AL, Currey KM, Newton SE, Rowlands DJ, Carroll AR. Potential secondary and tertiary structure in the genomic RNA of foot and mouth disease virus. Nucleic Acids Research. 1987;15(17):7067-7079. DOI: 10.1093/nar/15.17.7067
  10. 10. Zhu ZX, Yang F, Cao WJ, Liu HN, Zhang KS, Tian H, et al. The pseudoknot region of the 5′ untranslated region is a determinant of viral tropism and virulence of foot-and-mouth disease virus. Journal of Virology. 2019;93(8). DOI: ARTN e02039-18/10.1128/JVI.02039-18
  11. 11. Rieder E, Paul AV, Kim DW, van Boom JH, Wimmer E. Genetic and biochemical studies of poliovirus cis-acting replication element cre in relation to VPg uridylylation. Journal of Virology. 2000;74(22):10371-10380. DOI: 10.1128/jvi.74.22.10371-10380.2000
  12. 12. Mason PW, Bezborodova SV, Henry TM. Identification and characterization of a cis-acting replication element (cre) adjacent to the internal ribosome entry site of foot-and-mouth disease virus. Journal of Virology. 2002;76(19):9686-9694. DOI: 10.1128/Jvi.76.19.9686-9694.2002
  13. 13. Jackson RJ, Kaminski A. Internal initiation of translation in eukaryotes: The picornavirus paradigm and beyond. RNA. 1995;1(10):985-1000
  14. 14. Martinez-Salas E, Lopez de Quinto S, Ramos R, Fernandez-Miragall O. IRES elements: Features of the RNA structure contributing to their activity. Biochimie. 2002;84(8):755-763. DOI: 10.1016/S0300-9084(02)01408-6
  15. 15. Lopez de Quinto S, Martinez-Salas E. Interaction of the eIF4G initiation factor with the aphthovirus IRES is essential for internal translation initiation in vivo. RNA. 2000;6(10):1380-1392. DOI: 10.1017/s1355838200000753
  16. 16. Lopez de Quinto S, Lafuente E, Martinez-Salas E. IRES interaction with translation initiation factors: Functional characterization of novel RNA contacts with eIF3, eIF4B, and eIF4GII. RNA. 2001;7(9):1213-1226. DOI: 10.1017/s1355838201010433
  17. 17. Kanda T, Ozawa M, Tsukiyama-Kohara K. IRES-mediated translation of foot-and-mouth disease virus (FMDV) in cultured cells derived from FMDV-susceptible and -insusceptible animals. BMC Veterinary Research. 2016;12. DOI: 10.1186/s12917-016-0694-8
  18. 18. Galan A, Lozano G, Pineiro D, Martinez-Salas E. G3BP1 interacts directly with the FMDV IRES and negatively regulates translation. The FEBS Journal. 2017;284(19):3202-3217. DOI: 10.1111/febs.14184
  19. 19. Grubman MJ, Robertson BH, Morgan DO, Moore DM, Dowbenko D. Biochemical map of polypeptides specified by foot-and-mouth disease virus. Journal of Virology. 1984;50(2):579-586
  20. 20. Feng Q , Yu H, Liu YY, He CQ , Hu JS, Sang HC, et al. Genome comparison of a novel foot-and-mouth disease virus with other FMDV strains. Biochemical and Biophysical Research Communications. 2004;323(1):254-263. DOI: 10.1016/j.bbrc.2004.08.086
  21. 21. de Quinto SL, Saiz M, de la Morena D, Sobrino F, Martinez-Salas E. IRES-driven translation is stimulated separately by the FMDV 3′-NCR and poly(A) sequences. Nucleic Acids Research. 2002;30(20):4398-4405
  22. 22. Serrano P, Pulido MR, Saiz M, Martinez-Salas E. The 3′ end of the foot-and-mouth disease virus genome establishes two distinct long-range RNA-RNA interactions with the 5′ end region. The Journal of General Virology. 2006;87:3013-3022. DOI: 10.1099/vir.0.82059-0
  23. 23. Pulido MR, Sobrino F, Borrego B, Saiz M. Attenuated foot-and-mouth disease virus RNA carrying a deletion in the 3′ noncoding region can elicit immunity in swine. Journal of Virology. 2009;83(8):3475-3485. DOI: 10.1128/Jvi.01836-08
  24. 24. Biswal JK, Subramaniam S, Ranjan R, Pattnaik B. Partial deletion of stem-loop 2 in the 3′ untranslated region of foot-and-mouth disease virus identifies a region that is dispensable for virus replication. Archives of Virology. 2016;161(8):2285-2290. DOI: 10.1007/s00705-016-2909-5
  25. 25. Paprocka G. Foot-and-mouth disease virus and its molecular structure. Medycyna Weterynaryjna. 2006;62(7):753-756
  26. 26. Malik N, Kotecha A, Gold S, Asfor A, Ren J, Huiskonen JT, et al. Structures of foot and mouth disease virus pentamers: Insight into capsid dissociation and unexpected pentamer reassociation. PLoS Pathogens. 2017;13(9). DOI: 10.1371/journal.ppat.1006607
  27. 27. Doel TR, Baccarini PJ. Thermal stability of foot-and-mouth disease virus. Archives of Virology. 1981;70(1):21-32. DOI: 10.1007/bf01320790
  28. 28. Barteling SJ, Wagenaar F, Gielkens AL. The positively charged structural virus protein (VP1) of foot-and-mouth disease virus (type O1) contains a highly basic part which may be involved in early virus-cell interaction. The Journal of General Virology. 1982;62(Pt 2):357-361. DOI: 10.1099/0022-1317-62-2-357
  29. 29. Dawe PS, King AM. Point mutations in polypeptide VP1 of foot-and-mouth disease virus affect mouse virulence and BHK21 cell pathogenicity. Archives of Virology. 1983;76(2):117-126. DOI: 10.1007/bf01311695
  30. 30. Baxt B, Morgan DO, Robertson BH, Timpone CA. Epitopes on foot-and-mouth disease virus outer capsid protein VP1 involved in neutralization and cell attachment. Journal of Virology. 1984;51(2):298-305
  31. 31. Robertson BH, Morgan DO, Moore DM. Location of neutralizing epitopes defined by monoclonal antibodies generated against the outer capsid polypeptide, VP1, of foot-and-mouth disease virus A12. Virus Research. 1984;1(6):489-500. DOI: 10.1016/0168-1702(84)90006-6
  32. 32. Iarov AV, Gel’fanov VM, Grechaninova LA, Surovoi A, Vol’pina OM, Ivanov VT, et al. Antigenic structure of foot-and-mouth virus. IV. Synthesis and immunogenic properties of new fragments of the VP1 protein of food-and-mouth virus strain A22. Bioorganicheskaia Khimiia. 1989;15(9):1193-1205
  33. 33. Volpina OM, Yarov AV, Zhmak MN, Kuprianova MA, Chepurkin AV, Toloknov AS, et al. Synthetic vaccine against foot-and-mouth disease based on a palmitoyl derivative of the VP1 protein 135-159 fragment of the A22 virus strain. Vaccine. 1996;14(14):1375-1380. DOI: 10.1016/s0264-410x(96)00038-2
  34. 34. Haydon D, Lea S, Fry L, Knowles N, Samuel AR, Stuart D, et al. Characterizing sequence variation in the VP1 capsid proteins of foot and mouth disease virus (serotype 0) with respect to virion structure. Journal of Molecular Evolution. 1998;46(4):465-475. DOI: 10.1007/Pl00006327
  35. 35. Fowler V, Bashiruddin JB, Belsham GJ, Stenfeldt C, Botner A, Knowles NJ, et al. Characteristics of a foot-and-mouth disease virus with a partial VP1 G-H loop deletion in experimentally infected cattle. Veterinary Microbiology. 2014;169(1-2):58-66. DOI: 10.1016/j.vetmic.2013.12.008
  36. 36. Logan D, Abu-Ghazaleh R, Blakemore W, Curry S, Jackson T, King A, et al. Structure of a major immunogenic site on foot-and-mouth disease virus. Nature. 1993;362(6420):566-568. DOI: 10.1038/362566a0
  37. 37. Sun M, Qian KX, Su N, Chang HY, Liu JX, Chen GF. Foot-and-mouth disease virus VP1 protein fused with cholera toxin B subunit expressed in Chlamydomonas reinhardtii chloroplast. Biotechnology Letters. 2003;25(13):1087-1092. DOI: 10.1023/A:1024140114505
  38. 38. Liu Y, Hu R, Zhang S, Zhang F, Li Z, Wei X, et al. Expression of the foot-and-mouth disease virus VP1 protein using a replication-competent recombinant canine adenovirus type 2 elicits a humoral antibody response in a porcine model. Viral Immunology. 2006;19(2):202-209. DOI: 10.1089/vim.2006.19.202
  39. 39. Zhuang J, You YJ, Chen B, Rao Z, Pan J. The immune responses of the fusion protein consisted of two copies of T-cell and B-cell epitopes of food-and-mouth disease virus VP1 type O and LTB and STI enterotoxins of Escherichia coli. Yi Chuan. 2006;28(5):557-562
  40. 40. Fan H, Tong T, Chen H, Guo A. Immunization of DNA vaccine encoding C3d-VP1 fusion enhanced protective immune response against foot-and-mouth disease virus. Virus Genes. 2007;35(2):347-357. DOI: 10.1007/s11262-007-0105-0
  41. 41. Ren XG, Xue F, Zhu YM, Tong GZ, Wang YH, Feng JK, et al. Construction of a recombinant BHV-1 expressing the VP1 gene of foot and mouth disease virus and its immunogenicity in a rabbit model. Biotechnology Letters. 2009;31(8):1159-1165. DOI: 10.1007/s10529-009-9988-2
  42. 42. Sedeh FM, Yazdanpanah S, Soleimanjahi H, Mahravani H, Shafaee K, Razavi MH, et al. Enhancement of immune responses against Iranian isolate of FMD-type O/IRN/1/2010 based on VP1 and human HSP70 genes and comparison with conventional vaccine. Acta Scientiae Veterinariae. 2014;42
  43. 43. Caridi F, Vazquez-Calvo A, Sobrino F, Martn-Acebes MA. The pH stability of foot-and-mouth disease virus particles is modulated by residues located at the pentameric interface and in the N terminus of VP1. Journal of Virology. 2015;89(10):5633-5642. DOI: 10.1128/Jvi.03358-14
  44. 44. Zhang W, Yang F, Zhu ZX, Yang Y, Wang ZF, Cao WJ, et al. Cellular DNAJA3, a novel VP1-interacting protein, inhibits foot-and-mouth disease virus replication by inducing lysosomal degradation of VP1 and attenuating its antagonistic role in the beta interferon signaling pathway. Journal of Virology. 2019;93(13). DOI: 10.1128/JVI.00588-19
  45. 45. Horsington J, Zhang ZD. Consistent change in the B-C loop of VP2 observed in foot-and-mouth disease virus from persistently infected cattle: Implications for association with persistence. Virus Research. 2007;125(1):114-118. DOI: 10.1016/j.virusres.2006.12.008
  46. 46. Xue M, Wang HW, Li W, Zhou GH, Tu YB, Yu L. Effects of amino acid substitutions in the VP2 B-C loop on antigenicity and pathogenicity of serotype Asia1 foot-and-mouth disease virus. Virology Journal. 2012;9. DOI: 10.1186/1743-422x-9-191
  47. 47. Vazquez-Calvo A, Caridi F, Sobrino F, Martin-Acebes MA. An increase in acid resistance of foot-and-mouth disease virus capsid is mediated by a tyrosine replacement of the VP2 histidine previously associated with VP0 cleavage. Journal of Virology. 2014;88(5):3039-3042. DOI: 10.1128/Jvi.03222-13
  48. 48. Sun P, Zhang SM, Qin XD, Chang XN, Cui XR, Li HT, et al. Foot-and-mouth disease virus capsid protein VP2 activates the cellular EIF2S1-ATF4 pathway and induces autophagy via HSPB1. Autophagy. 2018;14(2):336-346. DOI: 10.1080/15548627.2017.1405187
  49. 49. Ganji VK, Biswal JK, Lalzampuia H, Basagoudanavar SH, Saravanan P, Selvan RPT, et al. Mutation in the VP2 gene of P1-2A capsid protein increases the thermostability of virus-like particles of foot-and-mouth disease virus serotype O. Applied Microbiology and Biotechnology. 2018;102(20):8883-8893. DOI: 10.1007/s00253-018-9278-9
  50. 50. Biswal JK, Mohapatra JK, Bisht P, Subramaniam S, Sanyal A, Pattnaik B. A positively charged lysine residue at VP2 131 position allows for the enhanced adaptability of foot-and-mouth disease virus serotype A in BHK-21 cells. Biologicals. 2015;43(1):71-78. DOI: 10.1016/j.biologicals.2014.07.001
  51. 51. Salem R, El-Kholy AA, Ibrahim M. Eight novel single chain antibody fragments recognising VP2 of foot-and-mouth disease virus serotypes A, O, and SAT 2. Virology. 2019;533:145-154. DOI: 10.1016/j.virol.2019.05.012
  52. 52. Ali W, Habib M, Shahd M. Evaluation of PCR primers targeting the VP2 region of the foot-and-mouth disease virus for improved serotype detection. Turkish Journal of Veterinary and Animal Sciences. 2018;42(4):335-345. DOI: 10.3906/vet-1801-17
  53. 53. Liu WM, Yang BL, Wang MX, Liang WF, Wang HW, Yang DC, et al. Identification of a conserved conformational epitope in the VP2 protein of foot-and-mouth disease virus. Archives of Virology. 2017;162(7):1877-1885. DOI: 10.1007/s00705-017-3304-6
  54. 54. Mohapatra JK, Priyadarshini P, Pandey L, Subramaniam S, Sanyal A, Hemadri D, et al. Analysis of the leader proteinase (L-pro) region of type A foot-and-mouth disease virus with due emphasis on phylogeny and evolution of the emerging VP3(59)-deletion lineage from India. Virus Research. 2009;141(1):34-46. DOI: 10.1016/j.virusres.2008.12.012
  55. 55. Mohapatra JK, Sahu A, Pandey L, Sanyal A, Hemadri D, Pattnaik B. Genetic characterization of type A foot-and-mouth disease virus 3A region in context of the reemergence of VP3(59)-deletion lineage in India. Infection, Genetics and Evolution. 2009;9(4):483-492. DOI: 10.1016/j.meegid.2009.01.009
  56. 56. Mohapatra JK, Pandey LK, Sharma GK, Bank SK, Pawar SS, Palsamy R, et al. Multiplex PCR for rapid detection of serotype a foot-and-mouth disease virus variants with amino acid deletion at position 59 of the capsid protein VP3. Journal of Virological Methods. 2011;171(1):287-291. DOI: 10.1016/j.jviromet.2010.10.016
  57. 57. Biswal JK, Das B, Sharma GK, Khulape SA, Pattnaik B. Role of a single amino acid substitution of VP3 H142D for increased acid resistance of foot-and-mouth disease virus serotype A. Virus Genes. 2016;52(2):235-243. DOI: 10.1007/s11262-016-1294-1
  58. 58. Li D, Yang WP, Yang F, Liu HA, Zhu ZX, Lian KQ , et al. The VP3 structural protein of foot-and-mouth disease virus inhibits the IFN-beta signaling pathway. The FASEB Journal. 2016;30(5):1757-1766. DOI: 10.1096/fj.15-281410
  59. 59. Li D, Wei J, Yang F, Liu HN, Zhu ZX, Cao WJ, et al. Foot-and-mouth disease virus structural protein VP3 degrades Janus kinase 1 to inhibit IFN-gamma signal transduction pathways. Cell Cycle. 2016;15(6):850-860. DOI: 10.1080/15384101.2016.1151584
  60. 60. Qi LL, Wang KL, Chen HT, Liu XS, Lv JL, Hou ST, et al. Host microRNA miR-1307 suppresses foot-and-mouth disease virus replication by promoting VP3 degradation and enhancing innate immune response. Virology. 2019;535:162-170. DOI: 10.1016/j.virol.2019.07.009
  61. 61. Blanco E, McCullough K, Summerfield A, Fiorini J, Andreu D, Chiva C, et al. Interspecies major histocompatibility complex-restricted Th cell epitope on foot-and-mouth disease virus capsid protein VP4. Journal of Virology. 2000;74(10):4902-4907. DOI: 10.1128/Jvi.74.10.4902-4907.2000
  62. 62. Filgueira MP, Wigdorovitz A, Romera A, Zamorano P, Borca MV, Sadir AM. Detection and characterization of functional T-cell epitopes on the structural proteins VP2, VP3, and VP4 of foot and mouth disease virus O1 Campos. Virology. 2000;271(2):234-239. DOI: 10.1006/viro.2000.0281
  63. 63. Robertson BH, Grubman MJ, Weddell GN, Moore DM, Welsh JD, Fischer T, et al. Nucleotide and amino acid sequence coding for polypeptides of foot-and-mouth disease virus type A12. Journal of Virology. 1985;54(3):651-660
  64. 64. Cao X, Bergmann IE, Fullkrug R, Beck E. Functional analysis of the two alternative translation initiation sites of foot-and-mouth disease virus. Journal of Virology. 1995;69(1):560-563
  65. 65. Gradi A, Foeger N, Strong R, Svitkin YV, Sonenberg N, Skern T, et al. Cleavage of eukaryotic translation initiation factor 4GII within foot-and-mouth disease virus-infected cells: Identification of the L-protease cleavage site in vitro. Journal of Virology. 2004;78(7):3271-3278. DOI: 10.1128/Jvi.78.7.3271-3278.2004
  66. 66. Moral-Lopez P, Alvarez E, Redondo N, Skern T, Carrasco L. L protease from foot and mouth disease virus confers eIF2-independent translation for mRNAs bearing picornavirus IRES. FEBS Letters. 2014;588(21):4053-4059. DOI: 10.1016/j.febslet.2014.09.030
  67. 67. Shanmugam Y, Muthukrishnan M, Singanallur NB, Villuppanoor SA. Phylogenetic analysis of the leader proteinase (L-pro) region of Indian foot and mouth disease serotype O isolates. Veterinaria Italiana. 2015;51(1):31-37. DOI: 10.12834/VetIt.164.473.2
  68. 68. Rueckert RR, Wimmer E. Systematic nomenclature of picornavirus proteins. Journal of Virology. 1984;50(3):957-959
  69. 69. de Felipe P, Martin V, Cortes ML, Ryan M, Izquierdo M. Use of the 2A sequence from foot-and-mouth disease virus in the generation of retroviral vectors for gene therapy. Gene Therapy. 1999;6(2):198-208. DOI: 10.1038/sj.gt.3300811
  70. 70. de Felipe P, Hughes LE, Ryan MD, Brown JD. Co-translational, intraribosomal cleavage of polypeptides by the foot-and-mouth disease virus 2A peptide. The Journal of Biological Chemistry. 2003;278(13):11441-11448. DOI: 10.1074/jbc.M211644200
  71. 71. Buren S, Ortega-Villasante C, Otvos K, Samuelsson G, Bako L, Villarejo A. Use of the foot-and-mouth disease virus 2A peptide Co-expression system to study intracellular protein trafficking in Arabidopsis. PLoS One. 2012;7(12). DOI: 10.1371/journal.pone.0051973
  72. 72. Sun YF, Lin Y, Zhang JH, Zheng SP, Ye YR, Liang XX, et al. Double Candida antarctica lipase B co-display on Pichia pastoris cell surface based on a self-processing foot-and-mouth disease virus 2A peptide. Applied Microbiology and Biotechnology. 2012;96(6):1539-1550. DOI: 10.1007/s00253-012-4264-0
  73. 73. Liu XQ , Liu HY, Chen Q  J, Yang MM, Xin HY, Bai L, et al. Construction of foot-and-mouth disease virus 2A-based bicistronic expression vector and coexpression of two genes in goat mammary epithelial cells. Animal Production Science. 2013;53(4):335-341. DOI: 10.1071/An12235
  74. 74. Torres V, Barra L, Garces F, Ordenes K, Leal-Ortiz S, Garner CC, et al. A bicistronic lentiviral vector based on the 1D/2A sequence of foot-and-mouth disease virus expresses proteins stoichiometrically. Journal of Biotechnology. 2010;146(3):138-142. DOI: 10.1016/j.jbiotec.2010.01.017
  75. 75. Minskaia E, Nicholson J, Ryan MD. Optimisation of the foot-and-mouth disease virus 2A co-expression system for biomedical applications. BMC Biotechnology. 2013;13. DOI: 10.1186/1472-6750-13-67
  76. 76. Yen HH, Scheerlinck JPY. Biological activity of ovine IL-23 expressed using a foot-and-mouth disease virus 2A self-cleaving peptide. Cytokine. 2013;61(3):744-746. DOI: 10.1016/j.cyto.2013.01.014
  77. 77. Kjaer J, Belsham GJ. Modifications to the foot-and-mouth disease virus 2A peptide: Influence on polyprotein processing and virus replication. Journal of Virology. 2018;92(8). DOI: 10.1128/JVI.02218-17
  78. 78. Kjaer J, Belsham GJ. Selection of functional 2A sequences within foot-and-mouth disease virus; requirements for the NPGP motif with a distinct codon bias. RNA. 2018;24(1):12-17. DOI: 10.1261/rna.063339.117
  79. 79. Pan L, Zhang YG, Wang YL, Wang BQ , Wang WX, Fang YZ, et al. Foliar extracts from transgenic tomato plants expressing the structural polyprotein, P1-2A, and protease, 3C, from foot-and-mouth disease virus elicit a protective response in Guinea pigs. Veterinary Immunology and Immunopathology. 2008;121(1-2):83-90. DOI: 10.1016/j.vetimm.2007.08.010
  80. 80. Zhan-Bo Z, Ying X, Bo H, Chang L, Huijun LJ, Kuoshi JS, et al. Immunogenicity of foot and mouth disease virus type Asia 1 protein VP1-2A fused with a multi-epitope expressed in Pichia pastoris. Journal of Animal and Veterinary Advances. 2012;11(9):1512-1517
  81. 81. Kotla S, Vishanath BS, Dechamma HJ, Ganesh K, Suryanarayana VVS, Reddy GR. DNA vaccine (P1-2A-3C-pCDNA) co-administered with bovine IL-18 gives protective immune response against foot and mouth disease in cattle. Veterinary Microbiology. 2016;193:106-115. DOI: 10.1016/j.vetmic.2016.07.007
  82. 82. Zhu ZX, Wang GQ , Yang F, Cao WJ, Mao RQ , Du XL, et al. Foot-and-mouth disease virus viroporin 2B antagonizes RIG-I-mediated antiviral effects by inhibition of its protein expression. Journal of Virology. 2016;90(24):11106-11121. DOI: 10.1128/Jvi.01310-16
  83. 83. Li M, Xin T, Gao XT, Wu J, Wang XX, Fang LC, et al. Foot-and-mouth disease virus non-structural protein 2B negatively regulates the RLR-mediated IFN-beta induction. Biochemical and Biophysical Research Communications. 2018;504(1):238-244. DOI: 10.1016/j.bbrc.2018.08.161
  84. 84. Zhi XY, Zhang Y, Sun SQ , Zhang ZH, Dong H, Luo X, et al. NLRP3 inflammasome activation by foot-and-mouth disease virus infection mainly induced by viral RNA and non-structural protein 2B. RNA Biology. 2020;17(3):335-349. DOI: 10.1080/15476286.2019.1700058
  85. 85. Zhang ZW, Pan L, Ding YZ, Lv JL, Zhou P, Fang YZ, et al. eEF1G interaction with foot-and-mouth disease virus nonstructural protein 2B: Identification by yeast two-hybrid system. Microbial Pathogenesis. 2017;112:111-116. DOI: 10.1016/j.micpath.2017.09.039
  86. 86. Liu HS, Xue Q , Cao WJ, Yang F, Ma LN, Liu WJ, et al. Foot-and-mouth disease virus nonstructural protein 2B interacts with cyclophilin A, modulating virus replication. The FASEB Journal. 2018;32(12):6706-6723. DOI: 10.1096/fj.201701351
  87. 87. Fukai K, Morioka K, Ohashi S, Yamazoe R, Yoshida K, Sakamoto K. Differentiation of foot-and-mouth disease virus-infected pigs from vaccinated pigs using a Western blotting assay based on baculovirus-expressed nonstructural proteins 2C and 3D. The Journal of Veterinary Medical Science. 2008;70(12):1353-1357. DOI: 10.1292/jvms.70.1353
  88. 88. Lu ZJ, Zhang XL, Fu YF, Cao YM, Tian MN, Sun P, et al. Expression of the major epitope regions of 2C integrated with the 3AB non-structural protein of foot-and-mouth disease virus and its potential for differentiating infected from vaccinated animals. Journal of Virological Methods. 2010;170(1-2):128-133. DOI: 10.1016/j.jviromet.2010.09.016
  89. 89. Wu L, Jiang T, Lu ZJ, Yang YM, Sun P, Liang Z, et al. Development and validation of a prokaryotically expressed foot-and-mouth disease virus nonstructural protein 2C′ 3AB-based immunochromatographic strip to differentiate between infected and vaccinated animals. Virology Journal. 2011;8. DOI: 10.1186/1743-422x-8-186
  90. 90. Liu ZZ, Shao JJ, Zhao FR, Zhou GQ , Gao SD, Liu W, et al. Chemiluminescence immunoassay for the detection of antibodies against the 2C and 3ABC nonstructural proteins induced by infecting pigs with foot-and-mouth disease virus. Clinical and Vaccine Immunology. 2017;24(8). DOI: 10.1128/CVI.00153-17
  91. 91. Gladue DP, O’Donnell V, Baker-Branstetter R, Holinka LG, Pacheco JM, Fernandez-Sainz I, et al. Foot-and-mouth disease virus nonstructural protein 2C interacts with Beclin1, modulating virus replication. Journal of Virology. 2012;86(22):12080-12090. DOI: 10.1128/Jvi.01610-12
  92. 92. Wang JC, Wang YQ , Liu J, Ding L, Zhang QH, Li XQ , et al. A critical role of N-myc and STAT interactor (Nmi) in foot-and-mouth disease virus (FMDV) 2C-induced apoptosis. Virus Research. 2012;170(1-2):59-65. DOI: 10.1016/j.virusres.2012.08.018
  93. 93. Zheng W, Li XY, Wang JC, Li XQ , Cao H, Wang YQ , et al. A critical role of interferon-induced protein IFP35 in the type I interferon response in cells induced by foot-and-mouth disease virus (FMDV) protein 2C. Archives of Virology. 2014;159(11):2925-2935. DOI: 10.1007/s00705-014-2147-7
  94. 94. Kumar N, Sharma R, Kakker NK. Non-structural protein 3A for differentiation of foot-and-mouth disease infected and vaccinated animals in Haryana (India). Zoonoses and Public Health. 2007;54(9-10):376-382. DOI: 10.1111/j.1863-2378.2007.01075.x
  95. 95. Yakovleva AS, Shcherbakov AV, Kanshina AV, Mudrak NS, Fomina TA. Recombinant non-structural 3A, 3B and 3AB proteins of foot-and-mouth disease virus: Use in indirect ELISA for differentiation of vaccinated and infected cattle. Molecular Biology. 2006;40, 1:165-171
  96. 96. Gladue DP, O’Donnell V, Baker-Bransetter R, Pacheco JM, Holinka LG, Arzt J, et al. Interaction of foot-and-mouth disease virus nonstructural protein 3A with host protein DCTN3 is important for viral virulence in cattle. Journal of Virology. 2014;88(5):2737-2747. DOI: 10.1128/Jvi.03059-13
  97. 97. Pacheco JM, Gladue DP, Holinka LG, Arzt J, Bishop E, Smoliga G, et al. A partial deletion in non-structural protein 3A can attenuate foot-and-mouth disease virus in cattle. Virology. 2013;446(1-2):260-267. DOI: 10.1016/j.virol.2013.08.003
  98. 98. Stenfeldt C, Arzt J, Pacheco JM, Gladue DP, Smoliga GR, Silva EB, et al. A partial deletion within foot-and-mouth disease virus non-structural protein 3A causes clinical attenuation in cattle but does not prevent subclinical infection. Virology. 2018;516:115-126. DOI: 10.1016/j.virol.2018.01.008
  99. 99. Li D, Lei CQ , Xu ZS, Yang F, Liu HN, Zhu ZX, et al. Foot-and-mouth disease virus non-structural protein 3A inhibits the interferon-beta signaling pathway. Scientific Reports. 2016;6. DOI: 10.1038/srep21888
  100. 100. Pacheco JM, Henry TM, O’Donnell VK, Gregory JB, Mason PW. Role of nonstructural proteins 3A and 3B in host range and pathogenicity of foot-and-mouth disease virus. Journal of Virology. 2003;77(24):13017-13027. DOI: 10.1128/Jvi.77.24.13017-13027.2003
  101. 101. Kristensen T, Newman J, Guan SH, Tuthill TJ, Belsham GJ. Cleavages at the three junctions within the foot-and-mouth disease virus capsid precursor (P1-2A) by the 3C protease are mutually independent. Virology. 2018;522:260-270. DOI: 10.1016/j.virol.2018.07.010
  102. 102. Birtley JR, Knox SR, Jaulent AM, Brick P, Leatherbarrow RJ, Curry S. Crystal structure of foot-and-mouth disease virus 3C protease. The Journal of Biological Chemistry. 2005;280(12):11520-11527. DOI: 10.1074/jbc.M413254200
  103. 103. Armer H, Moffat K, Wileman T, Belsham GJ, Jackson T, Duprex WP, et al. Foot-and-mouth disease virus, but not bovine enterovirus, targets the host cell cytoskeleton via the nonstructural protein 3C(pro). Journal of Virology. 2008;82(21):10556-10566. DOI: 10.1128/Jvi.00907-08
  104. 104. Fan XX, Han SC, Yan D, Gao Y, Wei YQ , Liu XT, et al. Foot-and-mouth disease virus infection suppresses autophagy and NF-kappa B antiviral responses via degradation of ATG5-ATG12 by 3C(pro). Cell Death & Disease. 2017;8. DOI: 10.1038/cddis.2016.489
  105. 105. Prabhakaran VA, John L, Nagaraj V, Vijayapillai U, Reddy GR, Joyappa DH. 3D polymerase gene of foot and mouth disease virus is a potential target for siRNA mediated inhibition of viral replication. Indian Journal of Biotechnology. 2017;16(3):296-303
  106. 106. Basagoudanavar SH, Ranjitha HB, Hosamani M, Kolangath SM, Selvan RPT, Sreenivasa BP, et al. Efficient inhibition of foot-and-mouth disease virus replication in vitro by artificial microRNA targeting 3D polymerase. Acta Virologica. 2019;63(4):475-479. DOI: 10.4149/av_2019_407
  107. 107. Rai DK, Schafer EA, Singh K, McIntosh MA, Sarafianos SG, Rieder E. Repeated exposure to 5D9, an inhibitor of 3D polymerase, effectively limits the replication of foot-and-mouth disease virus in host cells. Antiviral Research. 2013;98(3):380-385. DOI: 10.1016/j.antiviral.2013.03.022
  108. 108. Rweyemamu M, Roeder P, Mackay D, Sumption K, Brownlie J, Leforban Y, et al. Epidemiological patterns of foot-and-mouth disease worldwide. Transboundary and Emerging Diseases. 2008;55(1):57-72. DOI: 10.1111/j.1865-1682.2007.01013.x
  109. 109. Jamal SM, Belsham GJ. Molecular epidemiology, evolution and phylogeny of foot-and-mouth disease virus. Infection, Genetics and Evolution. 2018;59:84-98. DOI: 10.1016/j.meegid.2018.01.020

Written By

Yaxin Wang and Meijun Liu

Submitted: 05 April 2020 Reviewed: 09 July 2020 Published: 05 November 2020